Acrux receives FDA approval for its generic version of EMLA® (Lidocaine 2.5% and Prilocaine 2.5%) Cream

Melbourne, Australia; 28 July 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic version of EMLA® (Lidocaine 2.5% and Prilocaine 2.5%) Cream. In June 2019, Acrux submitted an ANDA to seek approval from the FDA to market its generic version […]

Acrux receives approval from the FDA for its generic version of Jublia®

Melbourne, Australia; 22 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Company’s generic version of Jublia® (efinaconazole) topical solution, 10%. Key Points  FDA’s approval of the application represents an important milestone for Acrux, being its second approval […]

Acrux confirms patent challenge for generic version of Aczone®

Melbourne, Australia; 8 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) today announced that Almirall LLC has initiated patent litigation against Acrux in the U.S. District Court for the District of New Jersey, regarding the Company’s Paragraph IV Abbreviated New Drug Application (ANDA) for Dapsone Gel 7.5% (a generic version of Aczone® Gel, 7.5%), […]

Acrux Announces Board Appointment

Melbourne, Australia; 4 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce Mr Don Brumley has joined the Board as a Non-executive Director. Mr Brumley has 30 years’ experience as a senior partner of Ernst & Young, Oceania. He has extensive experience in IPOs, transactions and audit. Mr Brumley has advised […]

Acrux Receipt of R&D Tax Incentive Rebate – Overseas Finding Application for Acrux Pharma Pty Ltd

Link to Full Article Melbourne, Australia; 31 May 2021: As announced on 30 April 2021 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to confirm that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received approval from AusIndustry for an Advance and Overseas Finding application. The finding covers financial years 2018/19, […]

BIOSCIENCE MANAGERS: This biotech focused fund explains why it invested $15m in these 2 ASX stocks

Link to Full Article MoneyTalks is Stockhead’s regular recap of the ASX stocks and sectors that fund managers and analysts are looking at right now. Today we hear from BioScience Managers’ managing partner Dr Graham Crooke. BioScience Managers is an Australian life sciences investor established in 2003 and has a solid investment record making over 200 investments across […]

Acrux (ASX:ACR) receives $15M in applications for $2M SPP

Link to Full Article Acrux (ACR) has wrapped up a share purchase plan that was more than seven times oversubscribed after receiving approximately $15.1 million in applications The placement has since been scaled back to roughly $9.9 million, but still marks a significant increase on the $2 million it was initially seeking ACR says funds […]

Acrux receives FDA approval for its generic testosterone topical solution

Link to Full Article Melbourne, Australia; 12 January 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic product based on Perrigo’s Testosterone Topical Solution, 30mg/1.5mL. In August 2018, Acrux submitted an Abbreviated New Drug Application (‘ANDA’) to seek approval from […]

Acrux (ASX:ACR) pushes ahead with $2M SPP

Link to Full Article Acrux (ACR) is pushing ahead with its planned share purchase plan (SPP) by sending off a booklet to eligible shareholders. The pharmaceutical company first flagged plans to carry out a fundraise back in late-December, when it successfully netted $7.8 million via a placement. ACR is now hoping to raise an additional $2 […]